Alhassani RY, Bagadood RM, Balubaid RN, Barno HI, Alahmadi MO, Ayoub NA (2021) Drug therapies affecting renal function: an overview
In a randomized, double-blind, placebo-controlled trial, once-weekly exenatide (2 mg) administered for 48 weeks significantly improved motor scores in patients with PD, with benefits sustained even after treatment discontinuation ( Collectively, these findings indicate that incretin mimetics provide neuroprotection extending beyond metabolic regulation by targeting multiple pathogenic processes in PD, including mitochondrial dysfunction, neuroinflammation from oxidative stress, sirtuin dysregulation, insulin resistance, and S toxicity (Figure 2)
For example, in one cohort study of 125,474 patients (without type 2 diabetes) who initiated GLP-1s, 46.5% discontinued use within one year
Common community options include adding cagrilintide for satiety, adding MOTS-c for mitochondrial support, or adding a GH secretagogue (covered in the Advanced Recomp Stack) for lean mass
10.1530/JOE-21-0194 70 KulkarniA
Gracia Graells M, Alcolea Lpez JM